Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...

Clinical Trials Market OverviewThe Clinical Trials Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated between 2025 and 2034. As ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

GenSight Biologics announces efficacy and safety results for Lumevoq gene therapy at the conclusion of the REFLECT phase III clinical study: Paris Thursday, February 13, 2025, 17: ...

CHENNAI: In what is considered to be one of the most competitive sports in the country, shooter Saurabh Chaudhary had ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine. New Drug Application (NDA) Submission Expected in the ...

Good day, ladies and gentlemen, and welcome to the Medpace Fourth Quarter and Full-Year 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakers' ...